Literature DB >> 16200393

Serum creatine kinase elevation as a possible complication of therapy with olanzapine.

Evgeniy Perlov1, Ludger Tebartz van Elst, Martin Czygan, Emanuel Bubl, Dieter Ebert.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 16200393     DOI： 10.1007/s00210-005-0004-7

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN： 0028-1298            Impact factor:   3.000


× No keyword cloud information.
  9 in total

1.  Recurrence of neuroleptic malignant syndrome with olanzapine treatment.

Authors:  S Gheorghiu; H Y Knobler; D Drumer
Journal:  Am J Psychiatry       Date:  1999-11       Impact factor: 18.112

2.  Olanzapine-induced acute rhabdomyolysis-a case report.

Authors:  U Baumgart; R Schmid; H Spiessl
Journal:  Pharmacopsychiatry       Date:  2005-01       Impact factor: 5.788

3.  Marked elevations of serum creatine kinase activity associated with antipsychotic drug treatment.

Authors:  H Y Meltzer; P A Cola; M Parsa
Journal:  Neuropsychopharmacology       Date:  1996-10       Impact factor: 7.853

4.  Olanzapine-induced rhabdomyolysis.

Authors:  C J Rosebraugh; D A Flockhart; S U Yasuda; R L Woosley
Journal:  Ann Pharmacother       Date:  2001-09       Impact factor: 3.154

Review 5.  Neuroleptic malignant syndrome in an adolescent receiving olanzapine-lithium combination therapy.

Authors:  Neeraj Berry; Sapna Pradhan; Rajesh Sagar; Suresh Kumar Gupta
Journal:  Pharmacotherapy       Date:  2003-02       Impact factor: 4.705

6.  Atypical neuroleptic malignant syndrome associated with olanzapine.

Authors:  Roy R Reeves; Raphael A Torres; Vincent Liberto; Roy H Hart
Journal:  Pharmacotherapy       Date:  2002-05       Impact factor: 4.705

7.  Marked elevation of serum creatine kinase associated with olanzapine therapy.

Authors:  E L Marcus; A Vass; J Zislin
Journal:  Ann Pharmacother       Date:  1999-06       Impact factor: 3.154

Review 8.  Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia.

Authors:  J C Kando; J C Shepski; W Satterlee; J K Patel; S G Reams; A I Green
Journal:  Ann Pharmacother       Date:  1997-11       Impact factor: 3.154

9.  Neuroleptic malignant syndrome associated with olanzapine.

Authors:  G A Filice; B C McDougall; N Ercan-Fang; C J Billington
Journal:  Ann Pharmacother       Date:  1998-11       Impact factor: 3.154
  9 in total
  4 in total

1.  Acute rhabdomyolysis during treatment with amisulpride and metformin.

Authors:  Francesco Ursini; Elena Succurro; Alessandro Grembiale; Franco Arturi
Journal:  Eur J Clin Pharmacol       Date:  2009-12-18       Impact factor: 2.953

2.  Delayed-onset rhabdomyolysis related to olanzapine: a case report.

Authors:  Yen-Feng Lee; Wei-Chung Mao; Yueh-Ming Tai; Hsin-An Chang; Yu-Chen Kao; San-Yuan Huang; Nian-Sheng Tzeng
Journal:  Singapore Med J       Date:  2016-05       Impact factor: 1.858

3.  Serum creatine kinase elevation associated with olanzapine treatment.

Authors:  Bhaskar Punukollu; Helen Rutherford
Journal:  BMJ Case Rep       Date:  2008-11-20

Review 4.  Antipsychotic-induced elevation of creatine kinase: a systematic review of the literature and recommendations for the clinical practice.

Authors:  Zacharias G Laoutidis; Kanellos T Kioulos
Journal:  Psychopharmacology (Berl)       Date:  2014-10-16       Impact factor: 4.530
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.